PCM
NBIX icon

Parsons Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Parsons Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,500
Closed -$215K – 345
2015
Q2 		$215K Buy
+4,500
New +$191K 0.03% 321

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parsons Capital Management's NBIX Position: Q3 2015 in Review

Parsons Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2015, closing a stake of 4,500 shares — an estimated $215K sold.

Parsons Capital Management first reported a position in NBIX in Q2 2015 and held it in 1 quarter. The position peaked at $215K in Q2 2015. 207 funds tracked by Wall St. Rank hold NBIX as of Q3 2015.

  • Parsons Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2015 after selling out during the quarter.
  • Parsons Capital Management sold 4,500 Neurocrine Biosciences shares in Q3 2015, an estimated $215K.
  • Parsons Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 1 quarter.
  • Parsons Capital Management's Neurocrine Biosciences position peaked at $215K in Q2 2015.
  • 207 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2015.

Based on Parsons Capital Management's 13F filing for Q3 2015, filed 6 Nov 2015.